woven-admin, Author at Mineralys Therapeutics

ENDO 2026: Lorundrostat Modulates Heart Failure Risk Biomarkers in Participants With Uncontrolled Hypertension

ESH 2026 Presentation: Lorundrostat for Hypertension in CKD: Results From the LAUNCH-HTN Trial